GenSight Biologics Announces Its 2024 Financial Calendar

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

GenSight Biologics announces completion of a €5 million capital increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital

GenSight Biologics Reports Cash Position as of December 31, 2023, and Provides Business Update

Laurence Rodriguez, appointed CEO of GenSight Biologics in December 2023, joins the Company’s Board of Directors

GenSight Biologics Provides Business and Financial Update

GenSight Biologics appoints Laurence Rodriguez as Chief Executive Officer

GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris

GenSight Biologics announces a successful offering for an amount of approximately €4.7 million

GenSight Biologics announces launch of an offering for an indicative amount of €5 million that has received subscription commitments from new and existing shareholders totaling €4 million